The cells were cultured in DMEM (Gibco, Gaithersburg, USA) supplemented with 10% fetal bovine serum (Gibco, Gaithersburg, USA), 100 U/mL penicillin, and 100 g/mL streptomycin
Enhancing Absorption: Liquid forms and IV infusions typically offer better bioavailability
Tissue distributions at different time points are summarized in Figure 6
Clinical Background BPC-157 was introduced in 1993 and initially studied as a potential treatment for inflammatory bowel disease due to its anti-ulcer effects
Glutathione supports antioxidant defenses, detoxification pathways, cellular protection, and overall cellular health.*
The FDA-approved version of sermorelin (Geref) was discontinued in 2008 for commercial reasons unrelated to safety